Supriya Lifescience has reported a robust performance for the second quarter of fiscal year 2026, marking a significant recovery from the previous quarter and reaffirming its growth trajectory.

Financial Highlights

The company achieved a revenue of INR 200.00 crores in Q2 FY26, representing a 20% year-on-year growth and a substantial 38% sequential increase. This performance underscores the company's resilience and ability to overcome operational challenges effectively.

Key financial metrics for Q2 FY26 include:

The company's EBITDA stood at INR 73.00 crores, up 12% year-on-year and 41% sequentially, with an EBITDA margin of 36.00%, aligning with the company's guidance.

Operational Performance

Exports continue to be the cornerstone of Supriya Lifescience's business, accounting for 81% of Q2 FY26 revenues. The company has made significant progress in its backward integration efforts, with 79% of Q2 FY26 revenues now fully integrated, enhancing operational efficiency.

Growth Drivers and Future Outlook

Dr. Satish Wagh, Executive Chairman and Whole-Time Director, expressed confidence in the company's growth trajectory, stating, "We are very much confident that we will be able to achieve our guidance of 20% plus growth in revenue."

The company reaffirmed its guidance of achieving around 20% annual revenue growth, with EBITDA margins in the range of 33%-35%. Supriya Lifescience remains on track to reach its target of INR 1,000.00 crore revenue by FY27, supported by:

1. A healthy product pipeline
2. 3-4 new product launches planned for the current fiscal year
3. Steady demand across key therapeutic areas including Anesthetics, Anti-diabetics, Anti-anxiety, Vitamins, and ADHD treatments

New Developments and Expansions

The Ambernath facility, a significant milestone for the company's CDMO strategy, has started validation campaigns and is progressing as planned. Commercial contributions from this facility are expected to commence from Q4 of the current fiscal year.

Dr. Saloni Wagh, Managing Director, highlighted the company's expansion into high-potential markets, stating, "Our primary focus remains on expanding into other high potential related markets. We continue to strengthen our competitiveness edge through deep backward integration, robust regulatory credentials across major markets and a broad portfolio of different products."

Conclusion

Supriya Lifescience's Q2 FY26 results demonstrate the company's ability to navigate challenges and capitalize on growth opportunities. With a strong focus on exports, backward integration, and expansion into new markets, the company appears well-positioned to achieve its growth targets and create value for stakeholders.

Investors and market watchers will be keen to observe the company's performance in the coming quarters, particularly the ramp-up of the Ambernath facility and the impact of new product launches on overall revenue growth.

Supriya Lifescience Ltd, a prominent player in the pharmaceutical sector, has reported a strong financial performance for the second quarter of fiscal year 2026, demonstrating resilience and growth in a competitive market.

Revenue and Profitability

The company's revenue from operations witnessed a significant quarter-on-quarter increase, rising to ₹2,794.40 million in Q2 FY2026 from ₹2,463.50 million in the previous quarter. This robust top-line growth underscores Supriya Lifescience's expanding market presence and effective sales strategies.

The company's profitability also showed improvement, with net profit increasing to ₹504.27 million, compared to ₹461.49 million in the prior quarter. This growth in bottom-line figures reflects the company's ability to manage costs effectively while driving revenue growth.

Half-Year Performance

For the half year ended September 30, 2025, Supriya Lifescience reported total revenue from operations of ₹5,257.90 million, with a net profit of ₹965.76 million. These figures demonstrate the company's consistent performance over a longer period.

Financial Position

As of September 30, 2025, Supriya Lifescience maintains a strong balance sheet with cash and cash equivalents standing at ₹992.68 million. This healthy liquidity position indicates the company's financial stability and potential for future investments or expansion.

Corporate Governance

The financial results were approved by the Board of Directors during their meeting held on November 12, 2025. Prior to board approval, the results were reviewed by the Audit Committee and received a clean review report from the statutory auditors, underlining the company's commitment to transparency and regulatory compliance.

Conclusion

The consistent growth in revenue and profitability, coupled with a strong cash position, positions Supriya Lifescience well in the pharmaceutical sector. The company's performance in Q2 FY2026 reflects its ability to navigate market challenges and capitalize on opportunities.

Note: All figures are in Indian rupees and have been rounded to two decimal places where applicable.